AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks. On June 30, Morgan Stanley maintained an Overweight rating and ...

The global Botulinum Toxins Market, valued at US$8.1 billion in 2024 stood at US$8.9 billion in 2025 and is projected to ...

There’s really no such thing as a “no brainer” stock pick. I’d say that some opportunities are more compelling than others.

The author includes U.S. and Canadian names, organized by country. Each company comes with a business summary, plus a bull ...

The pharma began its outreach to the HS community well before securing Bimzelx’s approval in the indication. In the spring of ...

Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s closing price of $48.18 was below its 50-day moving average of $50.32 and the ...

AbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline AbbVie is acquiring Capstan Therapeutics, a startup with technology that enables in vivo ...

San Diego-based Capstan is developing a potential first-in-class therapy to treat certain autoimmune disease by changing ...

AbbVie Inc. (NYSE:ABBV) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the stock jumped 3.4% on the ...